BlackRock Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

BlackRock Group’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.2M	Buy	110,810 +24,288	+28%	+$243K	﹤0.01%	2045
2016 Q3	$887K	Buy	86,522 +3,289	+4%	+$35.8K	﹤0.01%	2090
2016 Q2	$1.09M	Buy	83,233 +2,994	+4%	+$39.2K	﹤0.01%	1932
2016 Q1	$883K	Buy	80,239 +6,199	+8%	+$55.1K	﹤0.01%	1999
2015 Q4	$680K	Sell	74,040 -326	-0.4%	-$2.73K	﹤0.01%	2079
2015 Q3	$516K	Buy	74,366 +2,637	+4%	+$22.6K	﹤0.01%	2190
2015 Q2	$704K	Buy	71,729 +41,436	+137%	+$377K	﹤0.01%	2132
2015 Q1	$268K	Buy	30,293 +3,885	+15%	+$30.9K	﹤0.01%	2394
2014 Q4	$232K	Hold	26,408	–	–	﹤0.01%	2478
2014 Q3	$182K	Buy	26,408 +24,722	+1,466%	+$148K	﹤0.01%	2482
2014 Q2	$9K	Hold	1,686	–	–	﹤0.01%	2797
2014 Q1	$8K	Hold	1,686	–	–	﹤0.01%	2719
2013 Q4	$8K	Sell	1,686 -91,504	-98%	-$440K	﹤0.01%	2635
2013 Q3	$473K	Buy	93,190 +91,504	+5,427%	+$510K	﹤0.01%	2247
2013 Q2	$8K	Buy	+1,686	New	+$8.02K	﹤0.01%	2576

Other funds holding SCLN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BlackRock Group's SCLN Position: Q4 2016 in Review

BlackRock Group increased its Sciclone Pharmaceuticals Inc (SCLN) stake by 28% in Q4 2016, buying an estimated $243K and bringing the position to 110,810 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

BlackRock Group first reported a position in SCLN in Q2 2013 and has held it in 15 quarters since. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

BlackRock Group held 110,810 shares of Sciclone Pharmaceuticals Inc worth $1.2M as of Q4 2016.
BlackRock Group bought 24,288 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $243K.
Sciclone Pharmaceuticals Inc made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2045 holding.
BlackRock Group first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and has held it in 15 quarters since.
153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.